Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 5/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.54 |
| ▸ | CALCR | P30988 | 3/20 | 0.52 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.50 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.50 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433218 | 0.91 | OPRD1 (0.57) | OPRD1OPRM1CALCRNMUR2NMUR1 | |
| SCHEMBL31433280 | 0.88 | CXCL8 (0.56) | — | |
| SCHEMBL31433412 | 0.88 | APLNR (0.58) | APLNROPRD1OPRM1NMUR2NMUR1 | |
| SCHEMBL31433368 | 0.86 | REN (0.52) | APLNROPRD1OPRM1NMUR2NMUR1 | |
| SCHEMBL31433327 | 0.86 | CALCR (0.47) | APLNROPRD1CALCR | |
| SCHEMBL30586607 | 0.84 | OPRD1 (0.54) | APLNROPRD1OPRM1CALCR | |
| SCHEMBL31433200 | 0.84 | RAMP3 (0.51) | APLNROPRD1OPRM1CALCRNMUR2 | |
| SCHEMBL31135242 | 0.83 | F2 (0.58) | APLNROPRD1OPRM1NMUR2NMUR1 | |
| SCHEMBL30842169 | 0.83 | NMUR2 (0.65) | APLNROPRD1OPRM1NMUR2NMUR1 | |
| SCHEMBL31433305 | 0.83 | OPRM1 (0.47) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | APLNR 2565/4885OPRD1 3640/4885OPRM1 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.